By Michele Maatouk
Date: Tuesday 02 Jun 2026
(Sharecast News) - Elementis shot higher on Tuesday after saying it will return around $35m of net cash proceeds to shareholders following completion of the sale of its pharmaceutical manufacturing business.
| Elementis backs FY outlook after 'strong' first ... | 29-Apr-2026 | ShareCast |
| Elementis names Trudy Schoolenberg as chair | 19-Mar-2026 | ShareCast |
| Elementis FY operating profit seen 'marginally a... | 21-Jan-2026 | ShareCast |
| Confirmation of Board changes | 02-Jan-2026 | ShareCast |
| Director/PDMR Shareholding | 24-Dec-2025 | ShareCast |
| Transaction in Own Shares | 22-Jun-2026 | 14:42 | RNS |
| Transaction in Own Shares | 22-Jun-2026 | 14:30 | RNS |
| Transaction in Own Shares | 15-Jun-2026 | 12:42 | RNS |
| Transaction in Own Shares | 08-Jun-2026 | 17:14 | RNS |
| Commencement of share buyback programme | 03-Jun-2026 | 07:00 | RNS |
| Will the UK's five big banks remain optimistic? | 30-Jul-2007 | The Independent |
| Market Report | 12-May-2007 | Sun |
| Market Report: Loss of US patents weighs on Glax... | 10-Mar-2007 | The Independent |
| Jeremy Warner's Outlook: Markets are relearning ... | 01-Mar-2007 | The Independent |
| The Investment Column: Elementis | 28-Feb-2007 | The Independent |
No recent information was found.
| Currency | UK Pounds |
| Share Price | 156.40p |
| Change Today | -1.60p |
| % Change | -1.01 % |
| 52 Week High | 176.60 |
| 52 Week Low | 142.60 |
| Volume | 478,415 |
| Shares Issued | 571.48m |
| Market Cap | £893.79m |
| RiskGrade | 191 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 5 |
| Buy | 1 |
| Neutral | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 7 |

| Latest | Previous | |
|---|---|---|
| Final | Interim | |
| Ex-Div | 30-Apr-26 | 14-Aug-25 |
| Paid | 29-May-26 | 26-Sep-25 |
| Amount | 3.00¢ | 1.30¢ |
| Time | Volume / Share Price |
| 16:47 | 4,129 @ 155.32p |
| 16:35 | 3,010 @ 156.40p |
| 16:35 | 213,616 @ 156.40p |
| 16:35 | 989 @ 156.40p |
| 16:35 | 36 @ 156.40p |
| CEO | Luc van Ravenstein |
| CFO | Kath Kearney-Croft |
You are here: research